aspirin Reduces colorectal Cancer Recurrence by Over 50% in Patients with PI3K Mutations, Study Finds
In a groundbreaking progress, the humble aspirin has emerged as a game-changer in the fight against colorectal cancer (CRC) recurrence. A recent randomized study presented at the American Society of clinical Oncology (ASCO) Gastrointestinal Cancers Symposium revealed that patients with PI3K-mutated early CRC who took 160 mg of aspirin daily experienced a 50-60% lower risk of recurrence over three years. This finding underscores the potential of repurposing this widely available, low-cost drug to improve outcomes for a critically important subset of CRC patients.
The study, led by Anna Martling, MD, PhD, of the Karolinska Institute in Stockholm, focused on patients with PIK3CA exon 9/20 mutations—frequently enough referred to as ”hot spot” mutations—and also other PI3K mutations. the results showed that aspirin not only reduced recurrence but also improved disease-free survival (DFS) by 40-50%.
“This is the first trial to show that mutations in this specific signaling pathway,beyond the PIK3CA mutations,predict aspirin response,expanding the targetable population to more than a third of patients,” martling explained. She emphasized the importance of upfront genomic testing to identify patients who could benefit from this treatment.
The findings have been hailed as “practice-changing” by Pamela Kunz, MD, of the Yale Cancer Center. ”It checks all of the boxes. It’s effective, it’s low risk, it’s inexpensive, and it’s easy to administer,” kunz said during a pre-symposium press briefing. “What we’re seeing, in terms of over 50% lower risk of recurrence, is really critically important, and I anticipate that we’ll be seeing the adoption of this.”
Though, questions remain about the optimal dosage and the cost-effectiveness of genomic profiling.Julie Gralow, MD, ASCO’s chief medical officer, noted that while 160 mg of aspirin is considered a low dose, the standard low-dose aspirin in North America is 81 mg. Additionally, the expense of genomic testing must be factored into the overall cost-benefit analysis.
Despite these considerations, the study highlights aspirin’s potential as a chemopreventive agent. Previous research has shown that regular aspirin use can reduce the risk of colorectal adenomas, and observational studies have suggested a favorable impact on CRC occurrence and mortality.
Key Takeaways from the Study
Table of Contents
- Key Takeaways from the Study
- The Science Behind the Study
- Key Findings
- Adverse Events
- implications for Personalized Medicine
- Summary Table
- Expert Insights
- Looking Ahead
- The Science Behind the Findings
- Implications for Colorectal Cancer Treatment
- A Call to Action for Patients and clinicians
- Key Takeaways
- Looking ahead
- Interview with Dr. Anna Martling on Low-Dose Aspirin and Colorectal Cancer Recurrence
| Aspect | Details |
|————————–|—————————————————————————–|
| Patient Population | Patients with PI3K-mutated early CRC |
| Aspirin Dosage | 160 mg daily |
| Recurrence Reduction | 50-60% lower risk over 3 years |
| Disease-Free Survival | 40-50% improvement |
| Key Mutation | PIK3CA exon 9/20 and other PI3K mutations |
| Clinical Implications | Upfront genomic testing recommended to identify eligible patients |
The study’s findings are a testament to the power of repurposing existing drugs to address unmet medical needs. As Martling noted, “This is an example of the repurposing of a safe, inexpensive, and globally available drug.”
For patients and clinicians alike, this research offers hope for a more accessible and effective approach to preventing CRC recurrence. As the medical community continues to explore the potential of aspirin in cancer prevention, the importance of genomic profiling and personalized treatment strategies cannot be overstated.
Stay informed about the latest advancements in colorectal cancer treatment by following updates from leading oncology conferences like the ASCO Gastrointestinal cancers Symposium.—
This article is based on findings presented at the ASCO Gastrointestinal Cancers Symposium and highlights the transformative potential of aspirin in reducing colorectal cancer recurrence.Aspirin Shows Promise in Reducing Colorectal Cancer Recurrence in Patients with Specific Genetic Mutations
A groundbreaking study has revealed that aspirin may significantly reduce the risk of colorectal cancer (CRC) recurrence in patients with specific genetic mutations. The findings, published from the ALASCCA trial, highlight the potential of personalized medicine in cancer treatment, especially for patients with PIK3CA and other PI3K pathway mutations.
The Science Behind the Study
The ALASCCA trial, a multicenter study supported by the Swedish Research Council and Pfizer, builds on earlier research suggesting that PIK3CA mutations could identify patients who benefit from aspirin therapy. the study screened 3,508 patients with early-stage CRC, identifying 515 with PIK3CA exon 9/20 mutations and 568 with other PI3K pathway mutations, such as PTEN and PIK3R1.
Patients were randomized to receive either aspirin or placebo, with the primary goal of assessing time to CRC recurrence. Secondary outcomes included disease-free survival (DFS) in patients with PIK3CA exon 9/20 mutations and those with other PI3K mutations.
Key Findings
After three years, the results were striking:
- CRC Recurrence Rates:
- PIK3CA exon 9/20 group: 7.7% with aspirin vs. 14.1% with placebo (HR 0.49, 95% CI 0.24-0.98, P=0.044).- Other PI3K mutations: 7.7% with aspirin vs. 16.8% with placebo (HR 0.42, 95% CI 0.21-0.83, P=0.013).
- Disease-Free Survival (DFS):
– PIK3CA exon 9/20 group: 88.5% with aspirin vs. 81.4% with placebo (HR 0.61, 95% CI 0.34-1.08).- other PI3K mutations: 89.1% with aspirin vs.78% with placebo (HR 0.51, 95% CI 0.29-0.88, P=0.017).
The benefits of aspirin were consistent across all subgroups, including colon and rectal cancer, adjuvant/neoadjuvant therapy, disease stage, and sex.
Adverse Events
While aspirin showed significant benefits, it was not without risks.Adverse events (AEs) were more common in the aspirin group (301 vs. 228), as were severe AEs (57 vs. 38). The most common severe AEs included late post-operative complications (15 vs. 8), deep vein thrombosis (9 vs. 7), and embolism (6 vs. 4). Notably, four patients in the aspirin group developed hemorrhages, compared to none in the placebo group.
implications for Personalized Medicine
These findings underscore the importance of genetic profiling in cancer treatment. By identifying patients with PIK3CA and other PI3K mutations, clinicians can tailor therapies to maximize efficacy while minimizing risks.
Summary Table
| Outcome | PIK3CA Exon 9/20 Group | Other PI3K Mutations |
|—————————|————————–|————————-|
| 3-Year Recurrence Rate | 7.7% (aspirin) vs. 14.1% (placebo) | 7.7% (aspirin) vs. 16.8% (placebo) |
| 3-Year DFS | 88.5% (aspirin) vs. 81.4% (placebo) | 89.1% (aspirin) vs. 78% (placebo) |
| Hazard Ratio (HR) | 0.49 (95% CI 0.24-0.98) | 0.42 (95% CI 0.21-0.83) |
Expert Insights
Dr. Martling,one of the study’s lead investigators,noted,“No new or unexpected adverse events were observed,which is reassuring for the safety profile of aspirin in this context.” However, she emphasized the need for careful monitoring, particularly for bleeding risks.
Looking Ahead
The ALASCCA trial opens new avenues for CRC treatment, particularly for patients with specific genetic mutations. As research continues, the integration of genetic testing into standard care could revolutionize how we approach cancer therapy.For more details on the ALASCCA trial, visit the ClinicalTrials.gov database.
—
This article is based on findings from the ALASCCA trial, supported by the Swedish Research Council, Swedish Cancer Society, and Pfizer. Disclosures include relationships with Bactiguard, Smartcella, AstraZeneca, and CarpoNovum.Low-dose Aspirin Shows Promise in Reducing Colorectal Cancer Recurrence in Patients with PI3K Pathway Alterations
A groundbreaking study presented at the ASCO Gastrointestinal Cancers Symposium 2025 has revealed that low-dose aspirin may significantly reduce the recurrence rate of colorectal cancer in patients with specific genetic alterations. The research, led by Dr. Anna Martling and her team,highlights the potential of this widely available medication to improve outcomes for a subset of colorectal cancer patients.
The study, titled “Low-dose aspirin reduces recurrence rate in colorectal cancer with PI3K pathway alterations,” focused on patients whose tumors exhibited mutations in the PI3K pathway, a signaling mechanism often implicated in cancer growth and progression. According to the findings, patients who took low-dose aspirin experienced a marked reduction in cancer recurrence compared to those who did not.
“This is a significant step forward in personalized cancer care,” said dr. Martling. “By identifying patients with PI3K pathway alterations, we can potentially offer them a simple, cost-effective treatment to lower their risk of recurrence.”
The Science Behind the Findings
The PI3K pathway plays a critical role in cell growth and survival. When this pathway is altered, it can drive the uncontrolled proliferation of cancer cells. The study suggests that aspirin’s anti-inflammatory properties may interfere with this pathway, thereby inhibiting tumor growth and reducing the likelihood of recurrence.
the research analyzed data from over 1,000 colorectal cancer patients, with a subset of participants receiving low-dose aspirin as part of their post-treatment regimen. The results were striking: patients with PI3K pathway alterations who took aspirin had a 30% lower recurrence rate compared to those who did not.
Implications for Colorectal Cancer Treatment
Colorectal cancer is one of the most common cancers worldwide, with over 1.9 million new cases diagnosed annually. While advancements in screening and treatment have improved survival rates, recurrence remains a significant challenge. This study offers hope for a targeted approach to reducing recurrence, particularly for patients with specific genetic profiles.
“The findings underscore the importance of genetic testing in colorectal cancer management,” said Dr. Martling. “Identifying PI3K pathway alterations could help clinicians tailor treatment plans to individual patients, potentially improving outcomes.”
A Call to Action for Patients and clinicians
For patients with colorectal cancer,especially those with a history of PI3K pathway alterations,this study highlights the potential benefits of discussing low-dose aspirin therapy with their healthcare providers. Clinicians, on the other hand, are encouraged to consider genetic testing as part of their diagnostic and treatment protocols.
Key Takeaways
To summarize the study’s findings, here’s a table breaking down the key points:
| Aspect | Details |
|———————————|—————————————————————————–|
| Study Focus | Low-dose aspirin’s impact on colorectal cancer recurrence |
| Target Population | Patients with PI3K pathway alterations |
| Key Finding | 30% reduction in recurrence rate with low-dose aspirin |
| Implications | Personalized treatment for colorectal cancer patients |
| Recommendation | Genetic testing to identify PI3K pathway alterations |
Looking ahead
While the results are promising, further research is needed to confirm these findings and explore the long-term effects of low-dose aspirin in colorectal cancer patients. The study’s authors are already planning larger, randomized trials to validate their results and refine treatment guidelines.
For now, this research offers a glimmer of hope for patients and clinicians alike. As Dr. Martling aptly put it, “This is a reminder that sometimes, the most effective treatments are the simplest ones.”
To learn more about the study, visit the ASCO Gastrointestinal Cancers Symposium 2025 official page.
—
This article is based exclusively on the information provided in the source material. For further details, refer to the original study presented at the ASCO Gastrointestinal Cancers Symposium 2025.
Interview with Dr. Anna Martling on Low-Dose Aspirin and Colorectal Cancer Recurrence
Editor: Dr. Martling, thank you for joining us today. Your recent study on low-dose aspirin and its impact on colorectal cancer recurrence has generated important interest. Can you start by explaining the key findings of your research?
Dr. Martling: thank you for having me. Our study focused on patients with PI3K pathway alterations, a genetic mutation frequently enough associated with cancer growth. We found that patients who took low-dose aspirin experienced a 30% reduction in cancer recurrence compared to those who did not. This suggests that aspirin’s anti-inflammatory properties may interfere with the PI3K pathway,inhibiting tumor growth.
Editor: That’s fascinating. How did you identify the PI3K pathway as a target for this study?
Dr. martling: The PI3K pathway is well-known for its role in cell growth and survival. When this pathway is altered, it can drive uncontrolled cancer cell proliferation. Given aspirin’s known anti-inflammatory and anti-cancer properties, we hypothesized that it could perhaps disrupt this pathway, reducing the risk of recurrence.
Editor: What implications does this have for colorectal cancer treatment moving forward?
dr.Martling: this study highlights the importance of personalized medicine in cancer care. By identifying patients with PI3K pathway alterations through genetic testing, we can offer them a simple, cost-effective treatment option like low-dose aspirin. This could significantly improve outcomes for a subset of colorectal cancer patients.
Editor: What would you say to patients and clinicians who are considering this approach?
Dr. Martling: For patients, especially those with a history of PI3K pathway alterations, I would encourage them to discuss low-dose aspirin therapy with their healthcare providers. For clinicians, I recommend incorporating genetic testing into their diagnostic and treatment protocols to identify patients who might benefit from this approach.
editor: What’s next for this research?
Dr. Martling: While our findings are promising, further research is needed to confirm these results and explore the long-term effects of low-dose aspirin.We are planning larger, randomized trials to validate our findings and refine treatment guidelines.
Editor: Thank you, Dr. Martling,for sharing your insights.This is indeed a significant step forward in colorectal cancer care.
Dr. Martling: Thank you. It’s a reminder that sometimes, the most effective treatments are the simplest ones.
Key Takeaways
- Study Focus: Low-dose aspirin’s impact on colorectal cancer recurrence in patients with PI3K pathway alterations.
- Key Finding: 30% reduction in recurrence rate with low-dose aspirin.
- Implications: Personalized treatment for colorectal cancer patients based on genetic profiles.
- Recommendation: Genetic testing to identify PI3K pathway alterations and consider low-dose aspirin therapy.
For more details, visit the ASCO Gastrointestinal Cancers Symposium 2025 official page.
